Drug Profile
Tozinameran and BNT 161 combination vaccine - BioNTech/Pfizer
Alternative Names: BNT162b2/BNT161 combination vaccine; Combination COVID-19 & Influenza - BioNTech/Pfizer; PF-07926307; Tozinameran/BNT-161 vaccine - BioNTech/Pfizer; Tozinameran/qIRV - BioNTech/PfizerLatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator BioNTech; Pfizer
- Class COVID-19 vaccines; Influenza virus vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III COVID 2019 infections; Influenza virus infections
Most Recent Events
- 28 Dec 2023 BioNTech in collaboration with Pfizer completes a phase-I clinical trials in COVID-2019 infections prevention (In volunteers) in USA (IM) (NCT05596734)
- 28 Dec 2023 BioNTech in collaboration with Pfizer completes a phase-I clinical trials in Influenza virus infections prevention (In volunteers) in USA (IM) (NCT05596734)
- 21 Dec 2023 BioNTech SE and Pfizer plans a phase III trial for Influenza virus infections and COVID-2019 infections prevention (In volunteers) in USA (NCT06178991)